The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Cleavable linkers in antibody–drug conjugates
Abstract
This tutorial review summarises the advances in the field of cleavable linker technologies for antibody–drug conjugates (ADCs).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Strategies and challenges for the next generation of antibody–drug conjugates
Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Agarwal, P., & Bertozzi, C. R. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5004982 · Cited by 605
Hamann, P. R., Hinman, L. M., Hollander, I., Beyer, C. F., Lindh, D., Holcomb, R., Hallett, W., Tsou, H.-R., Upeslacis, J., Shochat, D., et al. (2002) · Bioconjugate Chemistry · doi:10.1021/bc010021y · Cited by 594
Erickson, H. K., Park, P. U., Widdison, W. C., Kovtun, Y. V., Garrett, L. M., Hoffman, K., Lutz, R. J., Goldmacher, V. S., & Blättler, W. A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4489 · Cited by 584
Lyon, R. P., Bovee, T. D., Doronina, S. O., Burke, P. J., Hunter, J. H., Neff-LaFord, H. D., Jonas, M., Anderson, M. E., Setter, J. R., & Senter, P. D. (2015) · Nature Biotechnology · doi:10.1038/nbt.3212 · Cited by 557
Dubowchik, G. M., Firestone, R. A., Padilla, L., Willner, D., Hofstead, S. J., Mosure, K., Knipe, J. O., Lasch, S. J., & Trail, P. A. (2002) · Bioconjugate Chemistry · doi:10.1021/bc025536j · Cited by 555
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Staudacher, A. H., & Brown, M. P. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.367 · Cited by 540
Kovtun, Y. V., Audette, C. A., Ye, Y., Xie, H., Ruberti, M. F., Phinney, S. J., Leece, B. A., Chittenden, T., Blättler, W. A., & Goldmacher, V. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3973 · Cited by 479
Li, F., Emmerton, K. K., Jonas, M., Zhang, X., Miyamoto, J. B., Setter, J. R., Nicholas, N. D., Okeley, N. M., Lyon, R. P., Benjamin, D. R., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1795 · Cited by 340
Linkers Having a Crucial Role in Antibody–Drug Conjugates
Lu, J., Jiang, F., Lu, A., & Zhang, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17040561 · Cited by 285
Rossin, R., Versteegen, R. M., Wu, J., Khasanov, A., Wessels, H. J., Steenbergen, E. J., ten Hoeve, W., Janssen, H. M., van Onzen, A. H. A. M., Hudson, P. J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03880-y · Cited by 277
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Rossin, R., van Duijnhoven, S. M. J., ten Hoeve, W., Janssen, H. M., Kleijn, L. H. J., Hoeben, F. J. M., Versteegen, R. M., & Robillard, M. S. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00231 · Cited by 247
Erickson, H. K., Widdison, W. C., Mayo, M. F., Whiteman, K., Audette, C., Wilhelm, S. D., & Singh, R. (2010) · Bioconjugate Chemistry · doi:10.1021/bc900315y · Cited by 246
Anami, Y., Yamazaki, C. M., Xiong, W., Gui, X., Zhang, N., An, Z., & Tsuchikama, K. (2018) · Nature Communications · doi:10.1038/s41467-018-04982-3 · Cited by 226
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
Dan, N., Setua, S., Kashyap, V., Khan, S., Jaggi, M., Yallapu, M., & Chauhan, S. (2018) · Pharmaceuticals · doi:10.3390/ph11020032 · Cited by 220
Kellogg, B. A., Garrett, L., Kovtun, Y., Lai, K. C., Leece, B., Miller, M., Payne, G., Steeves, R., Whiteman, K. R., Widdison, W., et al. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100480a · Cited by 219
Dorywalska, M., Dushin, R., Moine, L., Farias, S. E., Zhou, D., Navaratnam, T., Lui, V., Hasa-Moreno, A., Casas, M. G., Tran, T.-T., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-1004 · Cited by 216
Dubowchik, G. M., & Firestone, R. A. (1998) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(98)00609-x · Cited by 188
Development and Properties of β-Glucuronide Linkers for Monoclonal Antibody−Drug Conjugates
Jeffrey, S. C., Andreyka, J. B., Bernhardt, S. X., Kissler, K. M., Kline, T., Lenox, J. S., Moser, R. F., Nguyen, M. T., Okeley, N. M., Stone, I. J., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0600214 · Cited by 181
Tiberghien, A. C., Levy, J.-N., Masterson, L. A., Patel, N. V., Adams, L. R., Corbett, S., Williams, D. G., Hartley, J. A., & Howard, P. W. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00062 · Cited by 164
Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody–Drug Conjugates
Caculitan, N. G., dela Cruz Chuh, J., Ma, Y., Zhang, D., Kozak, K. R., Liu, Y., Pillow, T. H., Sadowsky, J., Cheung, T. K., Phung, Q., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2391 · Cited by 164
Antibody Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN-38) for Targeted Cancer Chemotherapy
Moon, S.-J., Govindan, S. V., Cardillo, T. M., D’Souza, C. A., Hansen, H. J., & Goldenberg, D. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800719t · Cited by 159
Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
Dorywalska, M., Strop, P., Melton-Witt, J. A., et al. (2015) · Bioconjugate Chemistry · doi:10.1021/bc5005747 · Cited by 153
Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates
Pillow, T. H., Sadowsky, J., Zhang, D., Yu, S., Rosario, G. D., Xu, K., He, J., Bhakta, S., Ohri, R. V., Kozak, K. R., et al. (2016) · Chemical Science · doi:10.1039/c6sc01831a · Cited by 145
Kern, J. C., Cancilla, M. T., Dooney, D., Kwasnjuk, K., Zhang, R., Beaumont, M., Figueroa, I., Hsieh, S., Liang, L. A., Tomazela, D. M., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.5b12547 · Cited by 143
Milatuzumab–SN-38 Conjugates for the Treatment of CD74+ Cancers
Govindan, S. V., Cardillo, T. M., Sharkey, R. M., Tat, F. T., Gold, D. V., & Goldenberg, D. M. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1170 · Cited by 136
A Traceless Vascular‐Targeting Antibody–Drug Conjugate for Cancer Therapy
Bernardes, G. J. L., Casi, G., Trüssel, S., Hartmann, I., Schwager, K., Scheuermann, J., & Neri, D. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201106527 · Cited by 133
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: An update
Tranoy‐Opalinski, I., Legigan, T., Barat, R., Clarhaut, J. A., Thomas, M., Renoux, B., & Papot, S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.12.045 · Cited by 124
Gébleux, R., Stringhini, M., Casanova, R., Soltermann, A., & Neri, D. (2016) · International Journal of Cancer · doi:10.1002/ijc.30569 · Cited by 124
Discovery of Peptidomimetic Antibody–Drug Conjugate Linkers with Enhanced Protease Specificity
Wei, B. Q., Gunzner, J. L., Yao, H., Wang, T., Wang, J., Xu, Z., Chen, J., Wai, J. S. M., Nonomiya, J., Tsai, S. P., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01430 · Cited by 113
Burke, P., Senter, P. D., Meyer, D. W., Miyamoto, J. B., Anderson, M. E., Toki, B. E., Manikumar, G., Wani, M. C., Kroll, D. J., & Jeffrey, S. C. (2009) · Bioconjugate Chemistry · doi:10.1021/bc9001097 · Cited by 110
Kern, J. C., Dooney, D., Zhang, R., Liang, L. A., Brandish, P. E., Cheng, M. M., Feng, G., Beck, A., Bresson, D., Firdos, J., et al. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00337 · Cited by 95
Corso, A. D., Cazzamalli, S., Gébleux, R., Mattarella, M., & Neri, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00304 · Cited by 92
Cazzamalli, S., Corso, A. D., & Neri, D. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.023 · Cited by 88
Dipeptide-based highly potent doxorubicin antibody conjugates
Jeffrey, S. C., Nguyen, M. T., Andreyka, J. B., Meyer, D. L., Doronina, S. O., & Senter, P. D. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.09.081 · Cited by 82
Kolakowski, R. V., Haelsig, K. T., Emmerton, K. K., Leiske, C. I., Miyamoto, J. B., Cochran, J. H., Lyon, R. P., Senter, P. D., & Jeffrey, S. C. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601506 · Cited by 78
Pillow, T. H., Schutten, M. M., Yu, S., Ohri, R. V., Sadowsky, J., Poon, K. A., Solis, W. A., Zhong, F., Rosario, G. D., Go, M. A. T., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0641 · Cited by 72
DiJoseph, J. F., Dougher, M. M., Armellino, D. C., Kalyandrug, L. B., Kunz, A., Boghaert, E. R., Hamann, P. R., & Damle, N. K. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0260-5 · Cited by 64
Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates
Kolodych, S., Michel, C., Delacroix, S., Koniev, O., Ehkirch, A., Eberová, J., Cianférani, S., Renoux, B., Krężel, W., Poinot, P., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.008 · Cited by 62
Gébleux, R., Wulhfard, S., Casi, G., & Neri, D. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0480 · Cited by 61
Wang, Y., Fan, S., Zhong, W., Zhou, X., & Li, S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091860 · Cited by 53
Cited by
Antibody drug conjugate: the “biological missile” for targeted cancer therapy
Fu, Z., Li, S., Han, S., Shi, C., & Zhang, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00947-7 · Cited by 1,643
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Site-selective modification strategies in antibody–drug conjugates
Walsh, S. J., Bargh, J. D., Dannheim, F. M., Hanby, A. R., Seki, H., Counsell, A. J., Ou, X., Fowler, E., Ashman, N., Takada, Y., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00310g · Cited by 461
Self-citationAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- Bargh, J. D., Isidro-Llobet, A., Parker, J. S., & Spring, D. R.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 48
- Issue
- 16
- Pages
- 4361-4374
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2958576566
- Cited by
- 652
- References
- 46
- FWCI
- 11.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.